Repositorio Dspace

Listar por autor "Vachova, Marta"

Listar por autor "Vachova, Marta"

Ordenar por:Orden:Resultados:

  • Surcinelli, Andrea; Kalincik, Tomas; Roos, Izanne; D'amico, Emanuele; Lechner-Scott, Jeannette; Ozakbas, Serkan; Hradilek, Pavel; Horakova, Dana; Vachova, Marta; Panzera, Ivan; Ruzza, Stefano; Piscaglia, María-Grazia; Gerlach, Oliver; Meca-Lallana, José-Eustasio; Valero-López, Gabriel; Kermode, Allan-G; Fabis-Pedrini, Marzena-J; Prevost, Julie; Ampapa, Radek; Hodgkinson, Suzanne; Grand'maison, Francois; Khoury, Samia-J; John, Nevin-A; Peterka, Marek; Houskova, Jana; Recmanova, Eva; Rous, Zuzana; Shaygannejad, Vahid; Alroughani, Raed; Kuhle, Jens; Jakob, Gregor-Brecl; Grammond, Pierre; Patti, Francesco; Van-Der-Walt, Anneke; Butzkueven, Helmut; Foschi, Matteo (SAGE PUBLICATIONS LTD, 2026-03)
    BACKGROUND: Late-onset multiple sclerosis (LOMS), defined by symptom onset after age 50, is increasingly recognised as a distinct clinical entity. Evidence comparing disease-modifying therapies (DMTs) in this subgroup ...
  • Roos, Izanne; Sharmin, Sifat; Horakova, Dana; Kubala-Havrdova, Eva; Libertinova, Jana; Vachova, Marta; Alroughani, Raed; Boz, Cavit; Rous, Zuzana; Buzzard, Katherine; Skibina, Olga; Peterka, Marek; Hradilek, Pavel; Mares, Miroslav; Coles, Alasdair; Brown, J-William-L; Eichau-Madueno, Sara; Foschi, Matteo; Prevost, Julie; Terzi, Murat; Prat, Alexandre; Girard, Marc; Meca-Lallana, José-Eustasio; John, Nevin; Blanco, Yolanda; van-der-Walt, Anneke; Butzkueven, Helmut; Recmanova, Eva; Laureys, Guy; Ampapa, Radek; Macdonell, Richard; Pavelek, Zbysek; Khoury, Samia-J; D'Amico, Emanuele; Gerlach, Oliver; Van-Pesch, Vincent; Maimone, Davide; Romero-Ferrando, Beatriz; McCombe, Pamela; Mrabet, Saloua; Willekens, Barbara; Cardenas-Robledo, Simón; Ramo-Tello, Cristina; Stourac, Pavel; Houskova, Jana; Shaygannejad, Vahid; Hodgkinson, Suzanne; Cartechini, Elisabetta; Kermode, Allan-G; Fabis-Pedrini, Marzena; Carroll, William-M; Slee, Mark; Sánchez-Menoyo, José-Luis; Al-Asmi, Abdullah; Mathey, Guillaume; Giannesini, Claire; Michel, Laure; Ciron, Jonathan; de-Seze, Jerome; Ruet, Aurelie; Kwiatkowski, Arnaud; Zephir, Helene; Papeix, Caroline; Lebrun-Frenay, Christine; Moreau, Thibault; Berger, Eric; Clavelou, Pierre; Pelletier, Jean; Casez, Olivier; Bourre, Bertrand; Wahab, Abir; Magy, Laurent; Camdessanche, Jean-Philippe; Doghri, Ines; Tchikviladze, Maia; Sellebjerg, Finn; Romme-Christensen, Jeppe; Jensen, Henrik-Boye; Illes, Zsolt; Bramow, Stephan; Rasmussen, Peter; Stilund, Morten-Leif; Schafer, Jakob; Kant, Matthias; Weglewski, Arkadiusz; Vukusic, Sandra; Magyari, Melinda; Laplaud, David-Axel; Kalincik, Tomas (BMJ PUBLISHING GROUP, 2026-05-20)
    BACKGROUND: Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, is a high-efficacy therapy for multiple sclerosis (MS). METHODS: Patients with relapse-onset MS treated with ocrelizumab, fingolimod, natalizumab or ...
  • Reardon, Patrick; Zhong, Michael; Horakova, Dana; Kermode, Allan-G; Fabis-Pedrini, Marzena; Vachova, Marta; Prevost, Julie; Lechner-Scott, Jeannette; van-der-Walt, Anneke; Pavelek, Zbysek; Stourac, Pavel; Stetkarova, Ivana; Meca-Lallana, José-Eustasio; McCombe, Pamela; Gross-Paju, Katrin; Millan-Pascual, Jorge; Kalincik, Tomas; Roos, Izanne; Lapointe, Emmanuelle; Houskova, Jana; Recmanova, Eva; Peterka, Marek; Ampapa, Radek; Jakob, Gregor-Brecl; Foschi, Matteo; Jokubaitis, Vilija; Butzkueven, Helmut (ELSEVIER SCI LTD, 2026-11)
    INTRODUCTION: Ofatumumab (OFA) is an emerging therapy for relapsing-remitting multiple sclerosis (RRMS), but the impact of prior disease-modifying therapy (pDMT) on outcomes after switching is unclear. OBJECTIVES: To ...